ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

CARA Cara Therapeutics Inc

0.77
-0.0352 (-4.37%)
May 18 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 253,065
Bid Price 0.60
Ask Price 1.07
News -
Day High 0.80

Low
0.50

52 Week Range

High
4.48

Day Low 0.75
Company Name Stock Ticker Symbol Market Type
Cara Therapeutics Inc CARA NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.0352 -4.37% 0.77 00:00:13
Open Price Low Price High Price Close Price Prev Close
0.80 0.75 0.80 0.7501 0.8052
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
1,842 253,065 $ 0.780874 $ 197,612 - 0.50 - 4.48
Last Trade Time Type Quantity Stock Price Currency
19:42:57 42 $ 0.80 USD

Cara Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
40.99M 54.66M - 20.97M -118.51M -2.17 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Cara Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No CARA Message Board. Create One! See More Posts on CARA Message Board See More Message Board Posts

Historical CARA Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.75750.870.7010.7595495370,7950.01251.65%
1 Month0.6850.870.640.7429652279,5160.08512.41%
3 Months0.821.150.63110.861193570,421-0.05-6.10%
6 Months1.111.310.500.786196688,083-0.34-30.63%
1 Year4.464.480.501.98843,746-3.69-82.74%
3 Years13.1618.930.507.92720,638-12.39-94.15%
5 Years18.9929.64730.5012.05696,900-18.22-95.95%

Cara Therapeutics Description

Cara Therapeutics Inc is an emerging biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.